The global market of diagnostic biomarkers for the detection of cardiovascular disease is expected to soar steadily at a compound annual growth rate (CAGR) of 12.8 percent between 2013 and 2018.

The March report titled “Cardiac Biomarkers: Technologies and Global Markets” was developed by BCC Research and announced April 10.

According to the report, the worldwide market for cardiac biomarkers was valued around $4 billion last year, up from an estimated $3.1 billion in 2012.

The report notes a trend during this five-year period in biomarkers for heart failure, especially ST2 and galectin-3, and others for the detection of stroke, including GFAP and S100-beta.

The biomarkers driving the market were listed as B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), C-reactive protein (CRP), choline, creatine kinase MB (CK-MB), D-dimer, glial fibrillary acidic protein (GFAP), heart fatty acid binding protein (H-FABP), ischemia-modified albumin (IMA), myeloperoxidase (MPO), myoglobin, soluble fragment CD40 ligand (sCD40L), and troponin I (cTnI) and troponin T (cTnT).